Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182

Devor,Eric J.; Schickling,Brandon M.; Reyes,Henry D.; Warrier,Akshaya; Lindsay,Brittany; Goodheart,Michael J.; Santillan,Donna A.; Leslie,Kimberly K.

doi:10.3892/or.2016.4605

Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182

Authors:
- Eric J. Devor
- Brandon M. Schickling
- Henry D. Reyes
- Akshaya Warrier
- Brittany Lindsay
- Michael J. Goodheart
- Donna A. Santillan
- Kimberly K. Leslie
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Published online on: February 1, 2016 https://doi.org/10.3892/or.2016.4605
Pages: 2461-2465

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Altered expression of cullin-5 (CUL5), a member of the cullin-RING E3 ubiquitin ligase family, has been implicated in a number of types of cancers including breast, cervical and hepatocellular cancers. In the present study, we found that CUL5 expression was significantly decreased in both endometrioid and serous endometrial adenocarcinomas with the more aggressive serous type displaying a higher reduction (-4.3-fold) than the less aggressive endometrioid type (-2.9-fold). Overexpression of CUL5 mRNA and protein in Ishikawa H endometrial cancer cells resulted in decreased cell proliferation and in a reduction in CUL5-RING E3 ligase downstream clients JAK2 and FAS-L. Finally, we demonstrated for the first time that CUL5 is a direct target of miR-182 that we previously showed to be significantly overexpressed in endometrial adenocarcinomas and we provided evidence that increased miR-182 expression is, at least in part, a result of demethylation of its upstream promoter. These data suggest a cascade in which miR-182 expression is epigenetically increased leading to decreased CUL5 expression and increased cellular proliferation. The final step in the cascade may be operating through a decrease in ubiquitination of pro-growth CUL5 ubiquitin ligase clients. This cascade offers a series of potential interventional steps involving epigenetic modification, miRNA and/or gene targeting and ubiquitination.

View Figures

View References

1	Petroski MD and Deshaies RJ: Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 6:9–20. 2005. View Article : Google Scholar : PubMed/NCBI
2	Burnatowska-Hledin MA, Kossoris JB, Van Dort CJ, Shearer RL, Zhao P, Murrey DA, Abbott JL, Kan CE and Barney CC: T47D breast cancer cell growth is inhibited by expression of VACM-1, a cul-5 gene. Biochem Biophys Res Commun. 319:817–825. 2004. View Article : Google Scholar : PubMed/NCBI
3	Johnson AE, Le IP, Buchwalter A and Burnatowska-Hledin MA: Estrogen-dependent growth and estrogen receptor (ER)-alpha concentration in T47D breast cancer cells are inhibited by VACM-1, a cul 5 gene. Mol Cell Biochem. 301:13–20. 2007. View Article : Google Scholar
4	Xu XM, Wang XB, Chen MM, Liu T, Li YX, Jia WH, Liu M, Li X and Tang H: MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett. 322:148–158. 2012. View Article : Google Scholar : PubMed/NCBI
5	Ma C, Qi Y, Shao L, Liu M, Li X and Tang H: Downregulation of miR-7 upregulates cullin 5 (CUL5) to facilitate G1/S transition in human hepatocellular carcinoma cells. IUBMB Life. 65:1026–1034. 2013. View Article : Google Scholar : PubMed/NCBI
6	American Cancer Society Cancer facts & figures 2014. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-041770.pdf. Accessed February 10, 2014.
7	Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al: SEER Cancer Statistics Review, 1975–2010. National Cancer Institute; Bethesda, MD, USA: http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER website, April 2014.
8	Devor EJ, Hovey AM, Goodheart MJ, Ramachandran S and Leslie KK: microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep. 26:995–1002. 2011.PubMed/NCBI
9	Rapti SM, Kontos CK, Papadopoulos IN and Scorilas A: Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. Clin Chem Lab Med. 52:1217–1227. 2014. View Article : Google Scholar : PubMed/NCBI
10	Albitar L, Pickett G, Morgan M, Davies S and Leslie KK: Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol. 106:52–64. 2007. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔ^C^T method. Methods. 25:402–408. 2001. View Article : Google Scholar
12	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative Ct method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar
13	Snedecor GW and Cochran WG: Statistical Methods. 8th edition. Iowa State University Press; Ames, IA: pp. 158–160. 1989
14	Stanic B, Katsuyama M and Miller FJ Jr: An oxidized extracellular oxidation-reduction state increases Nox1 expression and proliferation in vascular smooth muscle cells via epidermal growth factor receptor activation. Arterioscler Thromb Vasc Biol. 30:2234–2241. 2010. View Article : Google Scholar : PubMed/NCBI
15	Li LC and Dahiya R: MethPrimer: Designing primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002. View Article : Google Scholar : PubMed/NCBI
16	Hashimoto Y, Akiyama Y, Otsubo T, Shimada S and Yuasa Y: Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis. 31:777–784. 2010. View Article : Google Scholar : PubMed/NCBI
17	Burnatowska-Hledin M and Barney CC: New insights into the mechanism for VACM-1/cul5 expression in vascular tissue in vivo. Int Rev Cell Mol Biol. 313:79–101. 2014. View Article : Google Scholar : PubMed/NCBI
18	Burnatowska-Hledin M, Zhao P, Capps B, Poel A, Parmelee K, Mungall C, Sharangpani A and Listenberger L: VACM-1, a cullin gene family member, regulates cellular signaling. Am J Physiol Cell Physiol. 279:C266–C273. 2000.PubMed/NCBI
19	Van Dort C, Zhao P, Parmelee K, Capps B, Poel A, Listenberger L, Kossoris J, Wasilevich B, Murrey D, Clare P and Burnatowska-Hledin M: VACM-1, a cul-5 gene, inhibits cellular growth by a mechanism that involves MAPK and p53 signaling pathways. Am J Physiol Cell Physiol. 285:C1386–C1396. 2003. View Article : Google Scholar : PubMed/NCBI
20	Bradley SE, Johnson AE, Le IP, Oosterhouse E, Hledin MP, Marquez GA and Burnatowska-Hledin M: Phosphorylation of VACM-1/Cul5 by protein kinase A regulates its neddylation and antiproliferative effect. J Biol Chem. 285:4883–4895. 2010. View Article : Google Scholar :
21	Zhang Y, Wang X, Wang Z, Tang H, Fan H and Guo Q: miR-182 promotes cell growth and invasion by targeting forkhead box F2 transcription factor in colorectal cancer. Oncol Rep. 33:2592–2598. 2015.PubMed/NCBI
22	Li Y, Zhang D, Wang X, Yao X, Ye C, Zhang S, Wang H, Chang C, Xia H, Wang YC, et al: Hypoxia-inducible miR-182 enhances HIF1α signaling via targeting PHD2 and FIH1 in prostate cancer. Sci Rep. 5:124952015. View Article : Google Scholar
23	Sun J, Ji J, Huo G, Song Q and Zhang X: miR-182 induces cervical cancer cell apoptosis through inhibiting the expression of DNMT3a. Int J Clin Exp Pathol. 8:4755–4763. 2015.PubMed/NCBI
24	Liu S, Howell PM and Riker AI: Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells. Ann Surg Oncol. 20:1745–1752. 2013. View Article : Google Scholar
25	Zhou MJ, Chen FZ and Chen HC: Ubiquitination-involved enzymes and cancer. Med Oncol. 31:932014. View Article : Google Scholar
26	Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI